The Latest Breaking News from Medicare

Trump launches "TrumpRx" program to cut prices of Wegovy and Zepbound, making weight-loss drugs more affordable for Americans.

Nearly 10,000 people in America turn 65 every day. Why is that significant? It signals Medicare eligibility and shines a light on Medicare supplement insurance, known as Medigap.

Certain GLP-1 weight loss medications will be available for as little as $149 per month, a sharp drop from the current average retail price of $1,000–$1,350.

President Donald Trump unveiled a major pricing and coverage deal with drug giants Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) on Thursday, pledging to make blockbuster weight-loss drugs like Zepbound and Wegovy significantly cheaper and accessible for millions of Americans.

Down almost 50% from all-time highs, UnitedHealth stock trades at a compelling valuation while offering investors an attractive dividend yield.

President Donald Trump on Thursday announced agreements with Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) to significantly reduce prices for their GLP-1-based obesity and diabetes drugs.

Injectable versions of GLP-1s from Eli Lilly and Novo Nordisk will see reduced prices and broader coverage

America's waistline may shrink, but its national debt will swell.

You open the mail, and your stomach drops. The Medicare Summary Notice shows a service or item as “Denied.” It’s infuriating and, additionally, very scary. Many people simply give up and pay the bill. However, a denial is *not* the end of the road. You have the right to appeal,…

The pilot program could make it easier for seniors to use drugs like Wegovy and Zepbound.

Novo Nordisk and Eli Lilly become latest drug companies to bend knee to Trump’s ‘most-favored nation’ pricing plan